Neuroprotective effects of erythropoiesisstimulating agents in term and preterm neonates

作者：Messier Amber M; Ohls Robin K^*

来源：Current Opinion in Pediatrics, 2014, 26(2): 139-145.

DOI：10.1097/MOP.0000000000000077

• erythropoiesis-stimulating agents
• neurodevelopment
• neuroprotection
• oligodendrogenesis

Purpose of reviewThe use of erythropoiesis-stimulating agents (ESAs) such as erythropoietin and darbepoetin in preterm and term infants has been studied for over 20 years. Recent investigations have explored the potential neuroprotective effects of ESAs. We review the recent clinical trials and experimental animal models that provide evidence in support of using ESA to improve the neurodevelopmental outcomes in term and preterm infants.Recent findingsContinued work using animal models have confirmed the neuroprotective properties of ESAs, including promotion of oligodendrocyte development in the face of neuronal injury. Clinical studies in term and preterm infants have reported the neuroprotective effects following ESA administration, and improved neurodevelopmental outcomes have been reported in the studies of preterm infants.SummaryESAs show great promise in preventing and treating brain injury in term and preterm infants.

• 出版日期2014-4